AbangeLabsCAR-T access is no longer just a clinical story; HTA timing and cost-effectiveness design now shape who gets to market and when.
Commercial chimeric antigen receptor (CAR) T-cell access now depends on earlier health technology assessment (HTA) and cost-effectiveness design
A new 2 April 2026 Blood analysis shows that commercial chimeric antigen receptor (CAR) T-cell access is being constrained as much by health technology assessment (HTA) timing and cost-effectiveness uncertainty as by manufacturing, forcing evidence teams to pre-build comparative and economic strategy before approval.